Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Astellas Pharma and UMN Pharma have entered into a definitive agreement for UMN-0501 and UMN-0502 (Licensed Programs), which are cell culture based influenza vaccine programs developed by UMN Pharma, on 21 September 2010.
Subscribe to our email newsletter
UMN-0501 is a cell culture based H5N1 avian influenza vaccine, currently under preparation for Phase III clinical trial in Japan.
UMN-0502 is a cell culture based seasonal influenza vaccine, under preparation for Phase I/II clinical trial in Japan.
Under the agreement, Astellas will lead the further development and bear all the costs.
UMN Pharma will be responsible for manufacturing, supply of the final commercial products to Astellas, and Astellas will be selling the commercial products.